By determining the expression level of PLA2G7 in malignant and healthy prostate samples from 453 prostate cancer patients, the biomarker potential of PLA2G7 and the size of the potential patient group benefiting from PLA2G7 inhibition therapy, was evaluated. The gene discussed is PLA2G7; the disease is Familial prostate cancer.